4.5 Review

Applications of the CRISPR-Cas system for infectious disease diagnostics

期刊

EXPERT REVIEW OF MOLECULAR DIAGNOSTICS
卷 21, 期 7, 页码 723-732

出版社

TAYLOR & FRANCIS AS
DOI: 10.1080/14737159.2021.1922080

关键词

CRISPR-Cas systems; infectious diseases; diagnostics; COVID-19; Cas12 and Cas13

资金

  1. Science and Technology Innovation Plan from Weifang Medical University [041004]
  2. Science and Technology Development Fund (FDCT) of Macao SAR [FDCT/0014/2018/A1, FDCT/0117/2018/A3]
  3. University of Macau [MYRG2018-00158-FHS]
  4. National Natural Science Foundation of China [NSFC 81772980]

向作者/读者索取更多资源

This review summarizes the progress and applications of CRISPR-associated (Cas) systems in the diagnosis of infectious diseases, focusing on their early detection capabilities in different infectious diseases. Future development should focus on improving the specificity, sensitivity, and stability of diagnostic tools. The CRISPR-Cas approaches are expected to emerge as more promising and robust tools for infectious disease diagnosis in the future.
Introduction Rapid and accurate diagnostic approaches are essential for impeding the spread of infectious diseases. This review aims to summarize current progress of clustered regularly interspaced short palindromic repeats (CRISPR)-associated (Cas) systems in the applications for diagnostics of infectious diseases including the ongoing COVID-19 epidemic. Areas covered In this review, we discuss class 2 CRISPR-Cas biosensing systems-based diagnostics in various emerging and reemerging infectious diseases, CRISPR-Cas systems have created a new era for early diagnostics of infectious diseases, especially with the discovery of the collateral cleavage activity of Cas12 and Cas13. We mainly focus on different CRISPR-Cas effectors for the detection of pathogenic microorganisms as well as provide a detailed explanation of the pros and cons of CRISPR-Cas biosensing systems. In addition, we also introduce future research perspectives. Expert commentary However, further improvement of newly discovered systems and engineering existing ones should be developed to increase the specificity, sensitivity or stability of the diagnostic tools. It may be a long journey to finish the clinical transition from research use. CRISPR-Cas approaches will emerge as more promising and robust tools for infectious disease diagnosis in the future.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据